The influenza vaccine is manufactured using chicken egg embryos and as such, contains minimal residual quantities of ovalbumin (egg protein). In patients with an egg allergy, numerous clinical studies have demonstrated that its administration is safe with very little risk of anaphylactic reaction. Therefore, egg allergy is no longer a contra-indication to receiving TIV and these patients can now receive this vaccine without further precautions in CLSCs and doctors' offices[3 ,4 ]. There are no studies on the safety of LAIV administration in egg-allergic patients. As egg-allergic patients often have other atopic related comorbidities such as asthma, the increased protection against influenza which can be achieved with LAIV is desirable. The egg protein content in LAIV is comparable to that in TIV and its administration is intranasal rather than systemic. Therefore, it is reasonable to hypothesize that LAIV administration in egg-allergic patients is as safe as TIV administration in this same population. Yet, before recommending LAIV in egg-allergic patients, a study on its safety in this population is essential.